Hi @Nawab,
This is an excellent development because it says that Amoytop Biotech is confident that pevifsovir (ALG-000184, the best of the CAMs in clinical trials) will reach the market and be widely used.
John.
Dear @john.tavis,
Yes, this drug looks very promising. 2026 looks a very promising year for hepatitis drugs. I hope functional cure will be available before 2030 to majority of the people around the world.
Hi @Nawab @john.tavis @ThomasTu,
This deal with Amoytop is massive news for the community. Looking closely at the data, Pevifoscorvir (ALG-000184) genuinely looks like it could become a superior, long-term replacement for Vemlidy (TAF).
What makes it so compelling over standard NUCs are two major twists:
-
Zero metabolic, kidney, or mitochondrial pressure: Because it’s a CAM-E and doesn’t target human mitochondrial polymerase or renal transporter systems, it completely bypasses the off-target issues we see with long-term TAF/TDF use—no lipid spikes, no drug-induced weight gain, and no renal strain.
-
Active HBsAg reduction: While Vemlidy just keeps the virus asleep, the 96-week data on Pevifoscorvir shows that it actually drives progressive, long-term reductions in HBsAg and shrinks the cccDNA reservoir over time.
It acts like a much cleaner daily backbone. I actually just received a list of active B-SUPREME clinical trial sites in Eastern Europe (Romania and Moldova) directly from Aligos corporate, and I’ll be reaching out to one of them this week to explore screening. 2026 is looking like a major turning point!
Pevifoscorvir vs. Bepirovirsen, which one is likely to be effective in HBV chronic?
Hi @learnandshare,
Yes, sounds like interesting data. I look forward to the phase III data as it comes through.
Good question (and in full disclosure, I do advisory work for GSK), but from the clinical trials, Bepi has led to ~25% HBsAg clearance in people with HBsAg levels of less than 1000, and HBsAg decreases in many other patients. Pevi acts on the capsids so is not likely to induce as efficient HBsAg loss - which has been seen in their Phase II data of <10-fold decrease in HBsAg. As @learnandshare mentions, it’s more likely to be something to replace NUCs (if long-term data looks good) than something that induces a cure immediately.
Hope this helps,
Thomas
Yes! Pevi looks an amazing drug knocking down the virus from the source. But i hope that drugs like Pevi, Bepi and others in late stage reach markets as soon as possible.
Is there any ongoing research into using bepirovirsen in combination with other drugs—whether currently available or still under study—to boost its efficacy? Experts consistently point out that a functional cure will likely result from a drug cocktail or combination therapy; so, even with the current efficacy rates, this gives me hope for a future cure.
Dear @La.sciamachie,
Yes! Bepi is being tested with SiRNAs (Daplusiran/Tomligisiran) in phase 2 trial.
Hi all,
I’m also quite excited about Pevifoscorvir (ALG-000184). It is a really powerful drug.
I agree it could readily be paired with Bepi–that makes biological sense due to the vastly different mechanisms of action.
I also encourage caution about getting too excited about drugs that have not gone through full clinical testing. Numbers of treated patients are still relatively small at this point, and although things look great, the studies done so far don’t have the power to detect relatively rare side effects or side effects from long-term treatment.
So excitement is certainly warranted, but tempered with patience.
John.
I’m particularly happy to hear that #John Tavis is in agreement with this…